Medtronic plc, a global leader in healthcare technology, has announced a significant milestone in the regulatory review process for its INFUSE™ Bone Graft for Transforaminal Lumbar Interbody Fusion $(TLIF)$ procedure. Following a successful interim analysis, the independent Data Monitoring Committee recommended stopping further enrollment in the ongoing randomized controlled trial, citing early success. Medtronic is now preparing a Premarket Approval (PMA) submission to the U.S. Food and Drug Administration (FDA) to continue advancing this innovative spine surgery technology. Additionally, the company plans to apply for a New Technology Add-on Payment $(NTAP)$ with the U.S. Centers for Medicare & Medicaid Services, aiming to enhance the economic value of this innovation. This progress underscores Medtronic's commitment to bringing transformative technology to patients efficiently and responsibly.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.